WHAT IS SPRAVATO®?
SPRAVATO® is the first prescription nasal spray, taken with an oral antidepressant, for:
Adults with treatment-resistant depression
In the SPRAVATO® clinical trials, treatment-resistant depression was diagnosed in adults who were struggling with major depressive disorder and had not responded adequately to at least two different antidepressants of adequate dose and duration in the current episode.
Depressive symptoms in adults with major depressive disorder with suicidal thoughts or actions
SPRAVATO® is not for use as a medicine to prevent or relieve pain (anesthetic). It is not known if SPRAVATO® is safe and effective as an anesthetic medicine.
It is not known if SPRAVATO® is safe and effective for use in preventing suicide or in reducing suicidal thoughts or actions. SPRAVATO® is not for use in place of hospitalization if your healthcare provider determines that hospitalization is needed, even if the improvement is experienced after the first dose of SPRAVATO®.
It is not known if SPRAVATO® is safe and effective in children.
IMPORTANT:
The providers and staff at Insight Mental Wellness (IMW) will guide you every step of the way with a personalized program that’s grounded in science, based on proven practices, and optimized to help you break through the obstacles holding you back from fulfilling your potential.
We’re committed to being a patient, positive, and supportive ally throughout your journey.
Your journey is supported by our compassionate guides who are trained in psychedelic support, including preparation, navigation, and integration.
Ketamine is an NMDA receptor antagonist and interacts with the most abundant neurotransmitter system in your brain: glutamate. Research shows it increases expression of Brain-Derived Neurotrophic Factor (BDNF). This results in enhanced neuroplasticity, or the ability of brain cells to form new connections with one another. Ketamine has been an FDA-approved medication since 1970, and it is well-tolerated by patients ranging from young children to seniors.
Esketamine is a form of intranasal administered Ketamine treatment. It often provides a pleasant experience with little to no negative aftereffects. Esketamine is backed by substantial clinical research demonstrating its safety and efficacy for treatment of mental health disorders and often produces benefits within hours. Studies have shown response rates significantly higher than response rates with fewer lasting side effects.
It is FDA approved for Treatment for the following diagnosis:
- Major depression,
- Treatment-Resistant depression
- Post-traumatic stress disorder,
- Suicidal Ideation
- Anxiety disorder.
- Some off-label uses include treatment for OCD, and other mental health-related conditions.
- Your treatment plan will include psychotherapy sessions to help optimize your experience and achieve lasting change.
Ketamine has a safety record, but as with any medication, it is not without risks. Consult your clinician about the risks and any potential complications that may exclude you as a candidate before determining if it’s the right fit for you. Additionally, make sure to follow your medical team’s treatment plan and contact the clinic to let them know immediately if you experience any adverse reactions.
Some side effects of Esketamine treatment may include altered sense of time, anxiety, blurred vision, diminished ability to see/hear/feel, dry mouth, elevated blood pressure or heart rate, elevated intraocular or intracranial pressure, excitability, loss of appetite, mental confusion, nausea/vomiting, nystagmus (rapid eye movements), restlessness, slurred speech, synesthesia (a mingling of the senses).
Do not proceed with Esketamine treatment if any of the following apply to you:
- Allergic to ketamine and ketamine related products.
- Symptoms of psychosis or mania.
- Uncontrolled high blood pressure CHF or other serious heart problem.
- Severe breathing problem
History of elevated intraocular or intracranial pressure. - History of hyperthyroidism
Other serious medical illness
Under the age of 18 years old.
Pregnant, nursing, or trying to become pregnant.
Esketamine has been reported to produce issues including, but not limited to, those listed below. However, lasting adverse side-effects are rare when medical protocols are carefully followed.
Esketamine has been shown to cause moderate psychological dependency in some recreational users.
In rare cases, frequent, heavy users have reported increased frequency of urination, urinary incontinence, pain urinating, passing blood in the urine, or reduced bladder size
Esketamine may worsen problems in people with schizophrenia, severe personality disorders, or other serious mental disorders.
Users with a personal or family history of psychosis should be cautious using any psychoactive substance, including Esketamine, and discuss potential risks with your IMW clinician before proceeding with treatment.
The dissociative effects of Esketamine may increase patient vulnerability and the risk of accidents.
To promote positive outcomes and ensure safety, follow these Esketamine treatment guidelines:
Do not operate a vehicle (e.g., car, motorcycle, bicycle) or heavy machinery following treatment until you’ve had a full night of sleep (24 hours after treatment)
Refrain from taking benzodiazepines or stimulants for 24 hours prior to treatment
Continue to take antihypertensive medication as prescribed
Avoid hangovers or alcohol intake
Refrain from consuming solid foods within 3 hours prior to treatment and liquids within 1 hour prior to treatment
Esketamine treatment should never be conducted without a monitor present to ensure your safety
Ensure you have a safe form of transportation to and from the treatment session.